Line Abdul Rahman1, Tanya N Turan2, George Cotsonis3, Eyad Almallouhi4, Christine A Holmstedt5, Marc I Chimowitz6. 1. Department of Neurology, 96 Jonathan Lucas Street, Clinical Science Building 301, MSC 606, Medical University of South Carolina, Charleston 29425-8050, SC, United States. Electronic address: abdulara@musc.edu. 2. Department of Neurology, 96 Jonathan Lucas Street, Clinical Science Building 301, MSC 606, Medical University of South Carolina, Charleston 29425-8050, SC, United States. Electronic address: turan@musc.edu. 3. Department of Biostatistics and Bioinformatics, 1518 Clifton Rd, Emory University Rollins School of Public Health, Atlanta 30322, GA, United States. Electronic address: gcotson@emory.edu. 4. Department of Neurology, 96 Jonathan Lucas Street, Clinical Science Building 301, MSC 606, Medical University of South Carolina, Charleston 29425-8050, SC, United States. Electronic address: almallou@musc.edu. 5. Department of Neurology, 96 Jonathan Lucas Street, Clinical Science Building 301, MSC 606, Medical University of South Carolina, Charleston 29425-8050, SC, United States. Electronic address: holmsted@musc.edu. 6. Department of Neurology, 96 Jonathan Lucas Street, Clinical Science Building 301, MSC 606, Medical University of South Carolina, Charleston 29425-8050, SC, United States. Electronic address: mchimow@musc.edu.
Abstract
BACKGROUND: The safety and efficacy of dual antiplatelet use for symptomatic intracranial atherosclerosis beyond 90 days is unknown. Data from SAMMPRIS was used to determine if dual antiplatelet therapy (DAPT) beyond 90 days impacted the risk of ischemic stroke and hemorrhage. METHODS: This post hoc exploratory analysis from SAMMPRIS included patients who did not have a primary endpoint within 90 days after enrollment (n = 397). Patients in both the aggressive medical management (AMM) and percutaneous transluminal angioplasty and stenting (PTAS) arms were included. Baseline features and outcomes during follow-up were compared between patients who remained on DAPT beyond 90 days (on clopidogrel) and patients who discontinued clopidogrel and remained on aspirin alone at 90 days (off clopidogrel) using Fisher's exact tests. RESULTS: The stroke rate was numerically lower in the group on clopidogrel vs off clopidogrel among both the AMM alone arm (6.0% versus 10.8%, p = 0.31) and the PTAS arm (8.7% versus 9.8%; p = 0.82), but the difference was not significant. The major hemorrhage rates were numerically higher in the group on clopidogrel vs. off clopidogrel group among both the AMM alone arm (4.0% versus 2.5%; p = 0.67) and the PTAS arm (10.9% versus 3.5%; p = 0.08), but were not significant. CONCLUSION: This exploratory analysis suggests that prolonged DAPT use may lower the risk of stroke in medically treated patients with intracranial stenosis but may increase the risk of major hemorrhage.
RCT Entities:
BACKGROUND: The safety and efficacy of dual antiplatelet use for symptomatic intracranial atherosclerosis beyond 90 days is unknown. Data from SAMMPRIS was used to determine if dual antiplatelet therapy (DAPT) beyond 90 days impacted the risk of ischemic stroke and hemorrhage. METHODS: This post hoc exploratory analysis from SAMMPRIS included patients who did not have a primary endpoint within 90 days after enrollment (n = 397). Patients in both the aggressive medical management (AMM) and percutaneous transluminal angioplasty and stenting (PTAS) arms were included. Baseline features and outcomes during follow-up were compared between patients who remained on DAPT beyond 90 days (on clopidogrel) and patients who discontinued clopidogrel and remained on aspirin alone at 90 days (off clopidogrel) using Fisher's exact tests. RESULTS: The stroke rate was numerically lower in the group on clopidogrel vs off clopidogrel among both the AMM alone arm (6.0% versus 10.8%, p = 0.31) and the PTAS arm (8.7% versus 9.8%; p = 0.82), but the difference was not significant. The major hemorrhage rates were numerically higher in the group on clopidogrel vs. off clopidogrel group among both the AMM alone arm (4.0% versus 2.5%; p = 0.67) and the PTAS arm (10.9% versus 3.5%; p = 0.08), but were not significant. CONCLUSION: This exploratory analysis suggests that prolonged DAPT use may lower the risk of stroke in medically treated patients with intracranial stenosis but may increase the risk of major hemorrhage.
Authors: Ka Sing Lawrence Wong; Christopher Chen; Jianhui Fu; Hui Meng Chang; Nijasri C Suwanwela; Yining N Huang; Zhao Han; Kay Sin Tan; Disya Ratanakorn; Pavithra Chollate; Yudong Zhao; Angeline Koh; Qing Hao; Hugh S Markus Journal: Lancet Neurol Date: 2010-03-22 Impact factor: 44.182
Authors: Marc I Chimowitz; Michael J Lynn; Tanya N Turan; David Fiorella; Bethany F Lane; Scott Janis; Colin P Derdeyn Journal: J Stroke Cerebrovasc Dis Date: 2011 Jul-Aug Impact factor: 2.136
Authors: Marc I Chimowitz; Michael J Lynn; Harriet Howlett-Smith; Barney J Stern; Vicki S Hertzberg; Michael R Frankel; Steven R Levine; Seemant Chaturvedi; Scott E Kasner; Curtis G Benesch; Cathy A Sila; Tudor G Jovin; Jose G Romano Journal: N Engl J Med Date: 2005-03-31 Impact factor: 91.245
Authors: Sami Al Kasab; Michael J Lynn; Tanya N Turan; Colin P Derdeyn; David Fiorella; Bethany F Lane; L Scott Janis; Marc I Chimowitz Journal: J Stroke Cerebrovasc Dis Date: 2016-10-17 Impact factor: 2.136
Authors: Marc I Chimowitz; Michael J Lynn; Colin P Derdeyn; Tanya N Turan; David Fiorella; Bethany F Lane; L Scott Janis; Helmi L Lutsep; Stanley L Barnwell; Michael F Waters; Brian L Hoh; J Maurice Hourihane; Elad I Levy; Andrei V Alexandrov; Mark R Harrigan; David Chiu; Richard P Klucznik; Joni M Clark; Cameron G McDougall; Mark D Johnson; G Lee Pride; Michel T Torbey; Osama O Zaidat; Zoran Rumboldt; Harry J Cloft Journal: N Engl J Med Date: 2011-09-07 Impact factor: 91.245
Authors: Tanya N Turan; George Cotsonis; Michael J Lynn; Rahim H Wooley; Seegar Swanson; Janice E Williams; Barney J Stern; Colin P Derdeyn; David Fiorella; Marc I Chimowitz Journal: Cerebrovasc Dis Date: 2014-02-19 Impact factor: 2.762
Authors: S Claiborne Johnston; J Donald Easton; Mary Farrant; William Barsan; Robin A Conwit; Jordan J Elm; Anthony S Kim; Anne S Lindblad; Yuko Y Palesch Journal: N Engl J Med Date: 2018-05-16 Impact factor: 91.245
Authors: Colin P Derdeyn; Marc I Chimowitz; Michael J Lynn; David Fiorella; Tanya N Turan; L Scott Janis; Jean Montgomery; Azhar Nizam; Bethany F Lane; Helmi L Lutsep; Stanley L Barnwell; Michael F Waters; Brian L Hoh; J Maurice Hourihane; Elad I Levy; Andrei V Alexandrov; Mark R Harrigan; David Chiu; Richard P Klucznik; Joni M Clark; Cameron G McDougall; Mark D Johnson; G Lee Pride; John R Lynch; Osama O Zaidat; Zoran Rumboldt; Harry J Cloft Journal: Lancet Date: 2013-10-26 Impact factor: 79.321